CurrentmhnPolicy CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux)

Defines medical necessity, authorization, and continuation criteria for cetuximab (Erbitux) across specified cancer indications for Centene-affiliated health plans (Commercial, HIM, Medicaid). Applies to providers requesting coverage or prior authorization.

Policy Summary

Payermhn

PolicyClinical Policy: Cetuximab (Erbitux)

Policy CodePolicy CP.PHAR.317

Change TypeNo material changes

Effective DateFeb 1, 2017

Next Review Date

Key ActionProvider must submit documentation (office notes, labs, or other clinical information) demonstrating the member meets all indication-specific approval criteria when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6covered/allowed indication groups

400→250standard initial → maintenance dosing

6 motypical approval (Commercial)

12 motypical approval (Medicaid/HIM)

J9055HCPCS code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

infusion/cardiopulmonary

Coverage Criteria for Cetuximab (Erbitux)

Coverage with indication- and biomarker-based criteria

Coverage is supported for specific oncology indications with biomarker and disease-location constraints and combinations per NCCN; see indication-specific criteria in main policy.

Indications specified: Covered for labeled oncology indications including HNSCC and CRC when criteria met; place in therapy and required combinations or prior therapy are per NCCN compendium and policy revisions.

KRAS/NRAS/BRAF wild-type colon cancer: Must be KRAS/NRAS/BRAF wild-type AND tumor must be left-sided when used for unresectable synchronous or metachronous liver and/or lung metastases.

Safety: Recognize boxed warnings for infusion reactions and cardiopulmonary arrest; follow safe administration precautions as noted in Appendices.

Erbitux (cetuximab) is approved for specific oncology indications including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). For CRC, use is limited to K‑RAS/KRAS wild‑type (Ras‑wild-type) disease or other FDA‑recognized mutation‑directed pathways (e.g., BRAF V600E) as specified in the label. The product is not indicated for Ras‑mutant CRC or when Ras mutation test results are unknown; therefore requests for such indications are not supported by the labeled indications and require the off‑label documentation described elsewhere in this policy.

Non‑FDA approved indications that are not explicitly addressed in this policy are not authorized unless the request includes sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid). Providers must submit supporting clinical information per those off‑label policies to be considered for coverage.

When a requested use is outside the FDA‑approved indications included in this policy, approval will require submission of evidence demonstrating efficacy and safety for the specific indication. Such evidence should meet the standards and documentation requirements referenced in the payer’s off‑label use policies and evidence‑of‑coverage documents; absence of that documentation will prevent authorization.

Requests for non‑FDA approved indications that fail to provide the required off‑label evidence and documentation may be determined to be not medically necessary. Providers should follow the referenced off‑label use policies and include office notes, relevant diagnostic testing, tumor biomarker results, and supporting literature or compendia recommendations to avoid denial.

Regimens, Dosing, and Combination Therapies

Regimen	Indication / Line	Coverage status
{"text":"Cetuximab with FOLFIRI","status":""},{"text":"Metastatic colorectal cancer (KRAS/NRAS/BRAF wild-type) — first-line in combination with FOLFIRI","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Cetuximab with irinotecan","status":""},{"text":"Metastatic colorectal cancer — in combination with irinotecan for irinotecan-refractory patients","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Cetuximab single agent","status":""},{"text":"Metastatic colorectal cancer — single agent for patients who have failed oxaliplatin- and irinotecan-based chemotherapy or intolerant to irinotecan","status":"covered"},{"text":"Covered with criteria","status":""}

Regimen	Indication / Line	Coverage status
{"text":"Cetuximab with radiation","status":""},{"text":"Head and neck squamous cell carcinoma — locally or regionally advanced HNSCC in combination with radiation for initial treatment","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Cetuximab with platinum + 5-FU","status":""},{"text":"Recurrent locoregional or metastatic HNSCC — in combination with platinum-based therapy with fluorouracil for first-line treatment","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Cetuximab single agent","status":""},{"text":"Recurrent or metastatic HNSCC progressing after platinum-based therapy — single agent","status":"covered"},{"text":"Covered with criteria","status":""}

Regimen	Indication / Line	Coverage status
{"text":"Cetuximab + afatinib (Gilotrif)","status":""},{"text":"Non-small cell lung cancer (off-label) — tumor positive for qualifying EGFR mutations; prescribed in combination with afatinib as subsequent therapy after progression on an EGFR TKI","status":"experimental"},{"text":"Coverage only with supporting evidence/prior authorization may be required","status":""}

Dosing regimen / schedule	Common combination regimens / notes	Coverage status
{"text":"Weekly: initial 400 mg/m2 IV then 250 mg/m2 IV weekly","status":""},{"text":"Used for HNSCC and CRC; dose limits stated in policy; must be within FDA maximum or supported by guidelines","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Biweekly: 500 mg/m2 IV every 2 weeks","status":""},{"text":"Alternative dosing schedule for HNSCC and CRC; must be within FDA maximum or supported by guidelines","status":"covered"},{"text":"Covered with criteria","status":""}
{"text":"Combination regimens: FOLFOX, FOLFIRI, CapeOX, irinotecan-containing regimens (limited after prior therapy), select checkpoint inhibitor combinations per NCCN","status":""},{"text":"FOLFOX/CapeOX/FOLFIRI described in appendices; checkpoint inhibitor combinations referenced for HNSCC and select CRC subgroups per NCCN","status":"covered"},{"text":"Covered with criteria","status":""}

Biomarker and Molecular Test Requirements

inv-30: KRAS/NRAS/BRAF — wild-type or specified mutations

RequirementKRAS/NRAS/BRAF status: wild-type (no mutations) OR specific activating mutations as defined in indication (e.g., BRAF V600E, KRAS G12C).

ContextApplied primarily to metastatic colorectal cancer eligibility (advanced, recurrent, or metastatic CRC).

Left-sided limitationFor KRAS/NRAS/BRAF wild-type colon cancer with unresectable synchronous or metachronous liver and/or lung metastases, tumor must be left-sided (Appendix E).

inv-31: dMMR/MSI-H

BiomarkerDeficient mismatch repair (dMMR) / microsatellite instability-high (MSI-H).

Indication-specific requirementWhen dMMR/MSI-H CRC is present, member must be ineligible for or have progressed on checkpoint inhibitor immunotherapy before cetuximab is considered.

Coding and Dosing References

HCPCS CodesHCPCS

J9055

Injection, cetuximab, 10 mg

inv-14: Dosing regimens — initial 400 mg/m2 then 250 mg/m2 weekly OR 500 mg/m2 every 2 weeks

Weekly regimenInitial dose 400 mg/m2 IV followed by 250 mg/m2 IV weekly thereafter.

Biweekly regimen500 mg/m2 IV every 2 weeks (initial and subsequent doses for the biweekly schedule).

Dose limitsDose must not exceed the listed schedule unless supported by practice guidelines or peer‑reviewed literature (prescriber must submit evidence).

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization required. Provider must demonstrate indication‑specific criteria are met and submit supporting documentation (e.g., office chart notes, lab results, imaging, pathology reports) showing the member has met all approval criteria. Failure to provide required documentation or requesting coverage for non‑FDA indications without sufficient supporting evidence may result in denial.

Submit office notes, labs, pathology, and other clinical records supporting diagnosis and prior therapies as applicable.
Prior authorization must be obtained before initiation when criteria apply.

Documentation Required

Providers must submit documentation such as office chart notes, lab results, pathology, and other clinical information to support that the member meets the policy criteria. Documentation should specifically address the applicable indication, biomarker status, prior therapies tried, and rationale for off‑label regimens when requested.

Background

Cetuximab is a monoclonal antibody that antagonizes the epidermal growth factor receptor (EGFR) and is indicated in the label for select oncologic uses including HNSCC and certain forms of metastatic CRC. The FDA‑approved CRC indications include use in K‑Ras (Ras) wild‑type, EGFR‑expressing metastatic CRC (including combination with FOLFIRI or as single agent in specific refractory settings) and a BRAF V600E‑directed combination with encorafenib for BRAF V600E mutant metastatic CRC. The label also contains the clear limitation that Erbitux is not indicated for treatment of Ras‑mutant CRC or when Ras mutation status is unknown, and the product carries important safety warnings that should be reviewed prior to administration.

Definitions and Abbreviations

inv-24: epidermal growth factor receptor (EGFR) definition

DefinitionEpidermal growth factor receptor: EGFR.

ContextListed in Appendix A abbreviation/acronym key of the policy.

RelevanceTarget of cetuximab therapy and referenced in biomarker and mutation criteria for NSCLC and other indications.

inv-25: colorectal cancer (CRC) definition

DefinitionColorectal cancer (CRC): referenced abbreviation 'CRC' in Appendix A; includes advanced, recurrent, or metastatic disease in coverage criteria.

Clinical scopePolicy specifies CRC indications and biomarker-based eligibility (e.g., KRAS/NRAS/BRAF status, BRAF V600E, dMMR/MSI‑H, POLE/POLD1).

Policy Summary

Payermhn

PolicyClinical Policy: Cetuximab (Erbitux)

Policy CodePolicy CP.PHAR.317

Change TypeNo material changes

Effective DateFeb 1, 2017

Next Review Date

SourceLink

On This Page

Abbreviation sourcedMMR/MSI-H defined in Appendix A abbreviation key as 'deficient mismatch repair/microsatellite instability-high'.

inv-32: POLE/POLD1 — example TMB > 50 mut/Mb

BiomarkerPOLE/POLD1 mutation positive with ultrahypermutated phenotype.

Threshold exampleUltrahypermutated phenotype example: tumor mutation burden (TMB) > 50 mutations per megabase (mut/Mb).

Prior therapy requirementFor POLE/POLD1 mutation positive CRC, member must be ineligible for or have progressed on checkpoint inhibitor immunotherapy.

inv-33: EGFR mutation — exon 19 deletion or exon 21 L858R, S768I, L861Q, and/or G719X

Required mutationsEGFR sensitizing mutations required: exon 19 deletion or exon 21 L858R, S768I, L861Q, and/or G719X.

IndicationThis EGFR mutation requirement applies to the off-label NSCLC pathway where cetuximab is used in combination with afatinib as subsequent therapy.

Line-of-therapy noteDisease should have progressed on or after an EGFR TKI therapy prior to consideration of cetuximab plus afatinib.

inv-34: KRAS/NRAS/BRAF — wild-type; left-sided tumor requirement for specific metastatic settings

RequirementKRAS/NRAS/BRAF must be wild-type (no activating mutations) for specified CRC indications.

Tumor location constraintFor KRAS/NRAS/BRAF wild-type colon cancer with unresectable synchronous or metachronous liver and/or lung metastases, the primary tumor must be left-sided (splenic flexure to rectum).

Rationale referenceNCCN Colon Cancer Guidelines recommend left-sided tumor use only; right-sided tumors are unlikely to respond (Appendix E).

inv-35: BRAF V600E — V600E mutation positive

Mutation-specific requirementBRAF V600E mutation positive is an eligible biomarker for CRC when used in the indicated combinations (e.g., with Braftovi ± FOLFOX).

Line-of-therapy noteWhen BRAF V600E positive, cetuximab may be used in combination with Braftovi (encorafenib) with or without FOLFOX per policy language.

Policy updatePrior therapy requirement was removed when prescribed for BRAF V600E mutation positive in combination with encorafenib (Appendix/updates).

inv-36: EGFR sensitizing mutations — exon 19 deletion or exon 21 L858R, S768I, L861Q, and/or G719X

Sensitizing EGFR mutationsEGFR exon 19 deletion or exon 21 L858R, S768I, L861Q, and/or G719X are specified sensitizing mutations required for the NSCLC off-label pathway.

Combination therapyCetuximab is considered in combination with afatinib (Gilotrif) as subsequent therapy for these EGFR-mutant NSCLC cases.

Prior therapyDisease must have progressed on or after an EGFR TKI prior to cetuximab plus afatinib use; prior authorization for EGFR TKIs or Gilotrif may be required.

Include biomarker reports (e.g., KRAS/NRAS/BRAF, MSI/MMR, POLE/POLD1, EGFR) when relevant.
If requesting an off‑label use, include supporting peer‑reviewed literature or guideline references per policy.
Lack of adequate documentation for non‑FDA indications may result in denial per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53).

Denial Risk

Non‑FDA Indication Risk

Non‑FDA Indication Risk — requests for indications that are not FDA‑approved and not addressed in this policy require sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies. Insufficient supporting evidence or failure to follow referenced off‑label guidance may result in denial.

Off‑label requests must reference and meet criteria in CP.CPA.09 (Commercial), HIM.PA.154 (Marketplace), or CP.PMN.53 (Medicaid) as applicable.
Prescriber must submit supporting evidence (guidelines or peer‑reviewed literature) for off‑label regimens.

Prior Authorization

Checkpoint Inhibitor Requirement for Some CRC

Checkpoint inhibitor requirement for certain colorectal cancer biomarker subgroups: for dMMR/MSI‑H or POLE/POLD1 (ultrahypermutated) CRC, member must be ineligible for or have progressed on checkpoint inhibitor immunotherapy before cetuximab is approved.

Applicable to CRC with dMMR/MSI‑H or POLE/POLD1 mutation positive tumors (POLE/POLD1 requires ultrahypermutated phenotype, e.g., TMB > 50 mut/Mb).
Provide documentation of checkpoint inhibitor ineligibility or progression (treatment records, toxicity documentation, or progression imaging/notes).

Prior Authorization

Generic Trial Required for Brand‑Name Requests

Generic trial required for brand‑name requests when a generic equivalent is available: if a generic equivalent of cetuximab (or biosimilar where applicable) exists, providers must document a trial and failure or contraindication to the generic before requesting a brand‑name product.

Document attempted use of the generic equivalent and reason for brand request (e.g., intolerance, lack of efficacy, allergy, or clinical rationale).
If no generic/biosimilar is available, document unavailable status.

Billing Rule

Coding and Documentation

Billing/coding note: use HCPCS code J9055 for claims submission. Coding references in this policy are informational only and do not guarantee coverage—verify with current professional coding guidance prior to claim submission.

HCPCS: J9055 — Injection, cetuximab, 10 mg

Age criterionCoverage criteria for CRC require age ≥ 18 years for treated members.

inv-26: EGFR abbreviation entry

AbbreviationEGFR = epidermal growth factor receptor.

SourceAppendix A abbreviation/acronym key in the policy.

Clinical noteEGFR is the therapeutic target of cetuximab and appears in mutation eligibility language for NSCLC and other tumor types.

inv-27: CRC abbreviation entry

AbbreviationCRC = colorectal cancer.

SourceAppendix A abbreviation/acronym key in the policy.

UsageUsed throughout the policy to denote colorectal cancer in eligibility and biomarker criteria.